Animal models of disease are essential tools for studying the mechanisms of human disease occurrence and development, drug efficacy screenings, and therapeutic assessment (TA); excellent animal models created for a particular disease pathology can accelerate the development of new drugs. With the aim of helping domestic researchers to quickly easily obtain high-quality disease animal models from countries in Europe and the United States, Cyagen has formed a strong partnership with top animal model providers overseas (mainly biotech companies in Europe and the United States) to actively introduce animal models of superior quality. Simultaneously, Cyagen has invested heavily in research and development, recruited high-end talents, continued optimizing our suite of gene editing technologies, and has expanded the self-developed genetically engineered mouse model repository. Cyagen has additionally established a drug development and animal screening platform to serve research in cancer, immunity, endocrinology, cardiovascular disease (CVD), neurology, and infectious diseases. In short, Cyagen hopes to provide domestic researchers, CRO institutions, and new drug development institutions with world-class animal model services that meet every anticipated need and accelerate research progress worldwide!
Cancers and malignant tumors are among the major diseases that seriously endanger human health. Animal models of tumor are essential tools for studying the mechanisms of human tumor occurrence and development, drug efficacy screenings, and therapeutic assessment (TA). In accordance with your needs, Cyagen innovative animal model and drug development platform can provide various effective tumor models - such as immunodeficient nude mice, NOD SCID, C-NKG, immune checkpoint (ICP) humanized mice, syngeneic models, human tumor tissue xenograft models (CDX) – in addition to genetically modified models and phenotype analysis services. Furthermore, we can construct various subcutaneous, in situ, or metastatic tumor models to deliver highly customized in vivo pharmacodynamic services for your specific model requirements.
Proto-oncogenes and tumor suppressor genes (TSGs) are two types of genes in cells that are inseparable from the occurrence and development of tumors. The editing of specific suppressor genes or proto-oncogenes in specific types of cells in mice can produce corresponding tumors. Additionally, the mutation of a certain base in human cancer can be accurately copied into mouse or rat models to recapitulate the occurrence and development of human tumors.
Cyagen has served customers with thousands of genetically modified mouse/rat models related to tumor research and been cited in numerous articles and papers published in high-impact journals in the field of oncology such as Immunity, Nature Communications, Cancer Cell, PNAS, and more.
1. Yuan H, Han Y, Wang X, et al. SETD2 restricts prostate cancer metastasis by integrating EZH2 and AMPK signaling pathways[J]. Cancer Cell, 2020, 38(3): 350-365.
2. Zhang F, Li R, Yang Y, et al. Specific decrease in B-cell-derived extracellular vesicles enhances post-chemotherapeutic CD8+ T cell responses[J]. Immunity, 2019, 50(3): 738-750.
3. Zhou X A, Zhou J, Zhao L, et al. KLHL22 maintains PD-1 homeostasis and prevents excessive T cell suppression[J]. Proceedings of the National Academy of Sciences, 2020, 117(45): 28239-28250.
Immunodeficient mice refer to mice that are defective or lacking in a certain or more immune components (B cells, T cells, NK cells, etc.) in the immune system due to genetic mutations or artificial methods. This kind of mice are playing an increasingly important role in the research of immunity, tumor, stem cell and infectious disesea treatment. Congenital immunodeficient mice is commonly used in experimental research, which generally with genetic defects - such as nude mice, NOD scid, etc., and are often been used as the experimental animals for tumor models. Severe combined immunodeficient (SCID) mice are widely used in the construction of humanized mice due to their deficiency of T, B and NK immune cells, commonly used immunodeficient strains include NOG, NSG, BRGS, etc. Compared with nude mice, SCID mice and NOD scid，it's more easily to implanting into human tissues.
|Immunodeficient Mice||Research and Application|
|BALB/c nude Mice||Nude mice are ideal hosts for rapidly growing tumor cells because they are hairless and easy to observe and count tumor growth. However, they are not suitable hosts for lymphoma and leukemia studies because they retain B cells and strong NK cell responses.|
|NOD SCID Mouse||Immunodeficient mice lacking both T and B lymphocytes. Multiple immunological defects unique to this model provide an excellent system for reconstitution with human hematopoietic cells, resulting in exceptional models for HIV-1 research and gene therapy.|
|C-NKG Mice||NKG mouse lacks mature T, B and NK immune cells, so the complement activity is reduced and macrophage phagocytosis of human derived cells is weak. This model can efficiently transplant hematopoietic stem cells (HSC), peripheral blood mononuclear cells (PBMC), patient-derived xenograft (PDX) or adult stem cells and tissues, which is recognized as having high degree of immune deficiency and has good performance in the study of tumor, immunity, autoimmunity diseases, immunotherapy vaccine, GVHD/transplantation, safety evaluation, etc.|
The syngeneic model (also known as allograft mouse tumor systems) involves inoculation of tumor cell lines (derived from the same genetic background strain) which are implanted into the inbred immunocompetent mouse strain. The recipient mouse has an intact native immune system and normal immune response, and its immune system is compatible with the transplanted tumor tissue - which together maximize the simulation of the real-life tumor microenvironment. However, the transplanted mouse tissue may not fully represent the complexity of human tumors in clinical cases.
Cyagen can provide you with various transplantation mouse models for oncology research, such as mouse breast cancer, liver cancer, colon cancer, melanoma, lung cancer, brain cancer models, and drug efficacy evaluation services.
The cell line-derived xenograft (CDX) model, one of the commonly used models for studying tumor cell proliferation and in vivo drug screening, involves inoculation of tumor cells (subcultured in vitro) into immunodeficient mice. Due to the long-term cell passage in vitro, they have the characteristics of high homology, easy construction, and reproducibility. However, in the process of continuous culture and passage in vitro, tumor heterogeneity is quite different from the original tumor tissue.
Cyagen can provide you with a variety of effective CDX models for oncology research, such as breast cancer, liver cancer, bowel cancer, pancreatic cancer, lung cancer, stomach cancer, kidney cancer, prostate cancer, melanoma, bladder cancer, leukemia, ovarian cancer, brain cancer models, and drug efficacy evaluation services.
The activation of lymphocytes is a process involving multiple signals. The immune system needs to maintain an optimal balance between autoimmune disease prevention and tumor elimination. This balance is regulated by a series of costimulatory and inhibitory receptors/ligands, and the ligand/receptor pathways involved in this balance are called immune checkpoints. Immune checkpoint inhibitors are antibody drugs developed for the corresponding immune checkpoints, which mainly reactivate the anti-tumor immune response by blocking co-suppressive T cell signaling.
The amino acid sequence homology between the immune checkpoint genes of ordinary mice and the corresponding human genes is generally about 60%. However, under normal circumstances, antibodies that recognize human immune checkpoint proteins cannot identify the corresponding proteins in mice - which may be resolved with the humanization of mouse immune checkpoint genes.
Alongside the aging of society and the prevalence of obesity, the incidence of metabolic diseases is increasing yearly - which is a serious threat to human health. The most common metabolic diseases include obesity, type 2 diabetes caused by insulin resistance, and non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH).
Cyagen can provide metabolic disease models, such as obese mice, atherosclerosis, type 2 diabetes, and non-alcoholic fatty liver models, and drug efficacy evaluation services.